The JAK2 V617F somatic mutation, mortality and cancer risk in the general population

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. / Nielsen, Camilla; Birgens, Henrik S; Nordestgaard, Børge G; Kjaer, Lasse; Bojesen, Stig E.

In: Acta Haematologica Polonica, Vol. 96, No. 3, 2011, p. 450-3.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Nielsen, C, Birgens, HS, Nordestgaard, BG, Kjaer, L & Bojesen, SE 2011, 'The JAK2 V617F somatic mutation, mortality and cancer risk in the general population', Acta Haematologica Polonica, vol. 96, no. 3, pp. 450-3. https://doi.org/10.3324/haematol.2010.033191

APA

Nielsen, C., Birgens, H. S., Nordestgaard, B. G., Kjaer, L., & Bojesen, S. E. (2011). The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Acta Haematologica Polonica, 96(3), 450-3. https://doi.org/10.3324/haematol.2010.033191

Vancouver

Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Acta Haematologica Polonica. 2011;96(3):450-3. https://doi.org/10.3324/haematol.2010.033191

Author

Nielsen, Camilla ; Birgens, Henrik S ; Nordestgaard, Børge G ; Kjaer, Lasse ; Bojesen, Stig E. / The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. In: Acta Haematologica Polonica. 2011 ; Vol. 96, No. 3. pp. 450-3.

Bibtex

@article{9155a68b42784a58b5edbccb333c023c,
title = "The JAK2 V617F somatic mutation, mortality and cancer risk in the general population",
abstract = "JAK2 V617F is present in the majority of patients with myeloproliferative cancer; however, its prevalence and clinical significance in the general population is unknown. We screened for presence of the mutation in 10,507 participants from the Copenhagen City Heart Study with up to 17.6 years of follow up. Prevalence of the mutation was 0.2% (n=18). All 18 mutation positives died during follow up corresponding to a multifactorially adjusted hazard ratio for early death of 3.0 (95%CI:1.9-4.9). Corresponding hazard ratios for men versus women and 1-year age increases were 1.4 (1.1-1.9) and 1.1 (1.1-1.1). Multifactorially adjusted hazard ratios for any cancer, hematologic cancer and myeloproliferative cancer were 3.7 (1.7-8.0), 58 (13-261) and 161 (12-2,197), respectively. Corresponding hazard ratios were 1.2 (0.8-2.0), 2.3 (0.2-25), 1.3 (0.3-5.4) for men versus women, and 1.0 (1.0-1.1), 1.1 (0.9-1.2), 0.9 (0.8-1.1) for 1-year age increases. In the general population, JAK2 V617F is associated with increased morbidity and mortality, although only present in 18 of 10,507 (0.2%).",
author = "Camilla Nielsen and Birgens, {Henrik S} and Nordestgaard, {B{\o}rge G} and Lasse Kjaer and Bojesen, {Stig E}",
year = "2011",
doi = "http://dx.doi.org/10.3324/haematol.2010.033191",
language = "English",
volume = "96",
pages = "450--3",
journal = "Acta Haematologica Polonica",
issn = "0001-5814",
publisher = "Elsevier Urban & Partner Sp. z o.o.",
number = "3",

}

RIS

TY - JOUR

T1 - The JAK2 V617F somatic mutation, mortality and cancer risk in the general population

AU - Nielsen, Camilla

AU - Birgens, Henrik S

AU - Nordestgaard, Børge G

AU - Kjaer, Lasse

AU - Bojesen, Stig E

PY - 2011

Y1 - 2011

N2 - JAK2 V617F is present in the majority of patients with myeloproliferative cancer; however, its prevalence and clinical significance in the general population is unknown. We screened for presence of the mutation in 10,507 participants from the Copenhagen City Heart Study with up to 17.6 years of follow up. Prevalence of the mutation was 0.2% (n=18). All 18 mutation positives died during follow up corresponding to a multifactorially adjusted hazard ratio for early death of 3.0 (95%CI:1.9-4.9). Corresponding hazard ratios for men versus women and 1-year age increases were 1.4 (1.1-1.9) and 1.1 (1.1-1.1). Multifactorially adjusted hazard ratios for any cancer, hematologic cancer and myeloproliferative cancer were 3.7 (1.7-8.0), 58 (13-261) and 161 (12-2,197), respectively. Corresponding hazard ratios were 1.2 (0.8-2.0), 2.3 (0.2-25), 1.3 (0.3-5.4) for men versus women, and 1.0 (1.0-1.1), 1.1 (0.9-1.2), 0.9 (0.8-1.1) for 1-year age increases. In the general population, JAK2 V617F is associated with increased morbidity and mortality, although only present in 18 of 10,507 (0.2%).

AB - JAK2 V617F is present in the majority of patients with myeloproliferative cancer; however, its prevalence and clinical significance in the general population is unknown. We screened for presence of the mutation in 10,507 participants from the Copenhagen City Heart Study with up to 17.6 years of follow up. Prevalence of the mutation was 0.2% (n=18). All 18 mutation positives died during follow up corresponding to a multifactorially adjusted hazard ratio for early death of 3.0 (95%CI:1.9-4.9). Corresponding hazard ratios for men versus women and 1-year age increases were 1.4 (1.1-1.9) and 1.1 (1.1-1.1). Multifactorially adjusted hazard ratios for any cancer, hematologic cancer and myeloproliferative cancer were 3.7 (1.7-8.0), 58 (13-261) and 161 (12-2,197), respectively. Corresponding hazard ratios were 1.2 (0.8-2.0), 2.3 (0.2-25), 1.3 (0.3-5.4) for men versus women, and 1.0 (1.0-1.1), 1.1 (0.9-1.2), 0.9 (0.8-1.1) for 1-year age increases. In the general population, JAK2 V617F is associated with increased morbidity and mortality, although only present in 18 of 10,507 (0.2%).

U2 - http://dx.doi.org/10.3324/haematol.2010.033191

DO - http://dx.doi.org/10.3324/haematol.2010.033191

M3 - Journal article

VL - 96

SP - 450

EP - 453

JO - Acta Haematologica Polonica

JF - Acta Haematologica Polonica

SN - 0001-5814

IS - 3

ER -

ID: 40144855